Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Enlivex Therapeutics Ltd (NASDAQ: ENLV) closed at $0.83 up 0.40% from its previous closing price of $0.83. In other words, the price has increased by $0.40 from its previous closing price. On the day, 0.57 million shares were traded. ENLV stock price reached its highest trading level at $0.86 during the session, while it also had its lowest trading level at $0.8.
Ratios:
For a deeper understanding of Enlivex Therapeutics Ltd’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.43 and its Current Ratio is at 6.43. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on March 02, 2021, Reiterated its Buy rating but revised its target price to $33 from $22 previously.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENLV now has a Market Capitalization of 198189824 and an Enterprise Value of 2780086.
Stock Price History:
The Beta on a monthly basis for ENLV is 1.51, which has changed by -0.3266129 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, ENLV has reached a high of $2.10, while it has fallen to a 52-week low of $0.79. The 50-Day Moving Average of the stock is -17.42%, while the 200-Day Moving Average is calculated to be -22.44%.
Shares Statistics:
For the past three months, ENLV has traded an average of 3.75M shares per day and 941420 over the past ten days. A total of 24.29M shares are outstanding, with a floating share count of 23.17M. Insiders hold about 4.61% of the company’s shares, while institutions hold 4.41% stake in the company. Shares short for ENLV as of 1764288000 were 1147847 with a Short Ratio of 0.31, compared to 1761868800 on 88743. Therefore, it implies a Short% of Shares Outstanding of 1147847 and a Short% of Float of 0.49.
Earnings Estimates
A detailed examination of Enlivex Therapeutics Ltd (ENLV) is currently in progress, with 1.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.13 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.58 and -$0.58 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.58, with 2.0 analysts recommending between -$0.57 and -$0.59.
